Diaceutics PLC
LSE:DXRX

Watchlist Manager
Diaceutics PLC Logo
Diaceutics PLC
LSE:DXRX
Watchlist
Price: 116 GBX
Market Cap: 97.9m GBX
Have any thoughts about
Diaceutics PLC?
Write Note

Diaceutics PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Diaceutics PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Diaceutics PLC
LSE:DXRX
Additional Paid In Capital
ÂŁ37.1m
CAGR 3-Years
0%
CAGR 5-Years
227%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Additional Paid In Capital
ÂŁ698.6m
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Additional Paid In Capital
ÂŁ54.3m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
11%
Ergomed PLC
LSE:ERGO
Additional Paid In Capital
ÂŁ1m
CAGR 3-Years
-67%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Additional Paid In Capital
ÂŁ58.5m
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Additional Paid In Capital
ÂŁ516k
CAGR 3-Years
N/A
CAGR 5-Years
-49%
CAGR 10-Years
-19%
No Stocks Found

Diaceutics PLC
Glance View

Market Cap
98.3m GBX
Industry
Life Sciences Tools & Services

Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.

DXRX Intrinsic Value
155.87 GBX
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Diaceutics PLC's Additional Paid In Capital?
Additional Paid In Capital
37.1m GBP

Based on the financial report for Dec 31, 2023, Diaceutics PLC's Additional Paid In Capital amounts to 37.1m GBP.

What is Diaceutics PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
227%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top